Inventor · disambiguated record
Søren Ottosen
Also filed as: OTTOSEN SØREN
11 granted patents·10 pending applications·25 citations·filing 2014–2023
88Inventor score
Top patents by PatentIndex Score
21 records- 0191US10953034B2Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infectionHOFFMANN LA ROCHE·Filed 2018·Granted Mar 23, 2021·5 cites·24 claims
- 0289US10829555B2Oligonucleotides for reduction of PD-L1 expressionHOFFMANN LA ROCHE·Filed 2020·Granted Nov 10, 2020·3 cites·14 claims
- 0388US11484546B2Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infectionHOFFMANN LA ROCHE·Filed 2019·Granted Nov 1, 2022·3 cites·36 claims
- 0487US10745480B2Oligonucleotides for reduction of PD-L1 expressionHOFFMANN LA ROCHE·Filed 2019·Granted Aug 18, 2020·3 cites·30 claims
- 0586US11466081B2Oligonucleotides for reduction of PD-L1 expressionHOFFMANN LA ROCHE·Filed 2020·Granted Oct 11, 2022·2 cites·22 claims
- 0686US10421967B2Oligomers and oligomer conjugatesHOFFMANN LA ROCHE·Filed 2015·Granted Sep 24, 2019·4 cites·19 claims
- 0785US11534452B2Nucleic acid molecules for reduction of PAPD5 or PAPD7 mRNA for treating hepatitis B infectionHOFFMANN LA ROCHE·Filed 2017·Granted Dec 27, 2022·2 cites·18 claims
- 0885US10767181B2Oligomers and oligomer conjugatesHOFFMANN LA ROCHE·Filed 2019·Granted Sep 8, 2020·2 cites·13 claims
- 0982US12281307B2Oligomers and oligomer conjugatesHOFFMANN LA ROCHE·Filed 2023·Granted Apr 22, 2025·0 cites·1 claims
- 1082US11591598B2Oligomers and oligomer conjugatesHOFFMANN LA ROCHE·Filed 2020·Granted Feb 28, 2023·1 cites·13 claims
- 1170US2024182898A1ENHANCED OLIGONUCLEOTIDES FOR INHIBITING RTELl EXPRESSIONHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 1268US11898145B2Enhanced oligonucleotides for inhibiting RTEL1 expressionHOFFMANN LA ROCHE·Filed 2022·Granted Feb 13, 2024·0 cites·17 claims
- 1363US2020157546A1Antisense oligonucleotides for modulating htra1 expressionHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 1462US2023357773A1Oligonucleotide treatment of hepatitis b patientsHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 1562US2022042022A1Antisense oligonucleotides for modulating htra1 expressionHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 1659US2023119360A1Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbvHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 1757US2023123601A1Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbvHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 1855US2017283496A1Oligonucleotides for reduction of pd-l1 expressionROCHE INNOVATION CT COPENHAGEN AS·Filed 2017·Application pending·0 cites
- 1949US2022031730A1Enhanced oligonucleotides for modulating fubp1 expressionHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 2048US2019055564A1Antisense oligonucleotides for modulating htra1 expressionHOFFMANN LA ROCHE·Filed 2018·Application pending·0 cites
- 2142US2015368642A1Lna oligonucleotide carbohydrate conjugatesHOFFMANN LA ROCHE·Filed 2014·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Søren Ottosen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →